PAX3 and alveolar rhabdomyosarcoma: ARMS lacking the PAX3/7-FOXO1 fusion protein are molecularly and clinically indistinguishable from ERMS, together constitute the fusion-negative (FN)-RMS group (1, 5, 11), and have a better outcome, whereas FP-RMS is associated with significantly worse outcomes which led to current prospective clinical studies using fusion status rather than histology as risk stratifier (2, 12, 13).